TrialJournal of translational medicine2026

Fecal microbiota transplantation for advanced non-small cell lung cancer with secondary PD-1 resistance efficacy prognostic factors and microbiome diversity analysis.

Hongxiang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.